Gilead's China Remdesivir Patents Confirmed, Generics Firms Cautioned
US Firm Gains Upper Hand Amid Patent Dispute
Executive Summary
As the front-runner antiviral in the fight against the coronavirus gets increasingly positive attention in China, officials take action to keep the originator front and center and domestic copycats at bay.
You may also be interested in...
Hetero Head On Remdesivir Partnering, Royalty Model
Hetero is one of the new licensees for Gilead’s remdesivir, the investigational antiviral in the spotlight as a potential treatment for COVID-19, and the Indian group’s managing director shares insights on its supply chain readiness and the royalty model of the deal.
Biogen Still Not Disclosing Which Exec Has Coronavirus Infection
Public health officials in Massachusetts say Biogen company meeting is source of 70 cases in the state.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.